NATCO Pharma Limited (BOM:524816)

NATCO Pharma Statistics

Total Valuation

NATCO Pharma has a market cap or net worth of INR 149.01 billion. The enterprise value is 119.62 billion.

Market Cap	149.01B
Enterprise Value	119.62B

Important Dates

The next estimated earnings date is Friday, February 13, 2026.

Earnings Date	Feb 13, 2026
Ex-Dividend Date	Nov 20, 2025

Share Statistics

Current Share Class	179.11M
Shares Outstanding	n/a
Shares Change (YoY)	+0.00%
Shares Change (QoQ)	+0.02%
Owned by Insiders (%)	29.59%
Owned by Institutions (%)	10.51%
Float	83.32M

Valuation Ratios

The trailing PE ratio is 9.68 and the forward PE ratio is 15.53.

PE Ratio	9.68
Forward PE	15.53
PS Ratio	3.39
PB Ratio	1.72
P/TBV Ratio	1.78
P/FCF Ratio	11.14
P/OCF Ratio	8.51
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.08, with an EV/FCF ratio of 8.94.

EV / Earnings	7.77
EV / Sales	2.72
EV / EBITDA	7.08
EV / EBIT	8.04
EV / FCF	8.94

Financial Position

The company has a current ratio of 4.10, with a Debt / Equity ratio of 0.03.

Current Ratio	4.10
Quick Ratio	2.90
Debt / Equity	0.03
Debt / EBITDA	0.15
Debt / FCF	0.19
Interest Coverage	61.97

Financial Efficiency

Return on equity (ROE) is 19.44% and return on invested capital (ROIC) is 22.18%.

Return on Equity (ROE)	19.44%
Return on Assets (ROA)	9.95%
Return on Invested Capital (ROIC)	22.18%
Return on Capital Employed (ROCE)	17.04%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	10.46M
Profits Per Employee	3.66M
Employee Count	4,199
Asset Turnover	0.47
Inventory Turnover	0.97

Taxes

In the past 12 months, NATCO Pharma has paid 3.19 billion in taxes.

Income Tax	3.19B
Effective Tax Rate	17.17%

Stock Price Statistics

The stock price has decreased by -33.47% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-33.47%
50-Day Moving Average	886.23
200-Day Moving Average	876.77
Relative Strength Index (RSI)	39.09
Average Volume (20 Days)	60,491

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NATCO Pharma had revenue of INR 43.90 billion and earned 15.39 billion in profits. Earnings per share was 85.90.

Revenue	43.90B
Gross Profit	36.18B
Operating Income	14.87B
Pretax Income	18.55B
Net Income	15.39B
EBITDA	16.85B
EBIT	14.87B
Earnings Per Share (EPS)	85.90

Balance Sheet

The company has 32.04 billion in cash and 2.61 billion in debt, with a net cash position of 29.44 billion.

Cash & Cash Equivalents	32.04B
Total Debt	2.61B
Net Cash	29.44B
Net Cash Per Share	n/a
Equity (Book Value)	86.54B
Book Value Per Share	482.88
Working Capital	52.67B

Cash Flow

In the last 12 months, operating cash flow was 17.50 billion and capital expenditures -4.13 billion, giving a free cash flow of 13.38 billion.

Operating Cash Flow	17.50B
Capital Expenditures	-4.13B
Free Cash Flow	13.38B
FCF Per Share	n/a

Margins

Gross margin is 82.41%, with operating and profit margins of 33.88% and 35.05%.

Gross Margin	82.41%
Operating Margin	33.88%
Pretax Margin	42.26%
Profit Margin	35.05%
EBITDA Margin	38.39%
EBIT Margin	33.88%
FCF Margin	30.48%

Dividends & Yields

This stock pays an annual dividend of 3.50, which amounts to a dividend yield of 0.42%.

Dividend Per Share	3.50
Dividend Yield	0.42%
Dividend Growth (YoY)	-22.22%
Years of Dividend Growth	n/a
Payout Ratio	5.86%
Buyback Yield	-0.00%
Shareholder Yield	0.41%
Earnings Yield	10.33%
FCF Yield	8.98%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on November 26, 2015. It was a forward split with a ratio of 5.

Last Split Date	Nov 26, 2015
Split Type	Forward
Split Ratio	5

Scores

Altman Z-Score	n/a
Piotroski F-Score	4